Edoxaban for treatment of venous thromboembolism in patients with cancer: Rationale and design of the hokusai VTE-cancer study

Thrombosis and Haemostasis

Volumn 114, Issue 6, 2015, Pages 1268-1276

  van Es, Nick ^a   Di Nisio, Marcello ^b   Bleker, Suzanne M ^a   Segers, Annelise ^c   Mercuri, Michele F ^d   Schwocho, Lee ^d   Kakkar, Ajay ^e   Weitz, Jeffrey I ^f   Beyer Westendorf, Jan ^g   Boda, Zoltan ^h   Carrier, Marc ⁱ   Chlumsky, Jaromir ^j   Décousus, Hervé ^k   Garcia, David ^l   Gibbs, Harry ^m   Kamphuisen, Pieter W ⁿ   Monreal, Manuel ^o   Ockelford, Paul ^p   Pabinger, Ingrid ^q   Verhamme, Peter ^r   Grosso, Michael A ^d   Büller, Harry R ^a   Raskob, Gary E ^s   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b University Gabrielle d'Annunzio   (Italy)

^c ITREAS   (Netherlands)

^d DAIICHI SANKYO INC   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h UNIVERSITY OF DEBRECEN   (Hungary)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j CHARLES UNIVERSITY   (Czech Republic)

^k HÔPITAL NORD   (France)

^l UNIVERSITY OF WASHINGTON   (United States)

^m ALFRED HOSPITAL   (Australia)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p AUCKLAND CITY HOSPITAL   (New Zealand)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r UNIVERSITY OF LEUVEN   (Belgium)

^s UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

Anticoagulant drugs; Cancer; Clinical trial; Edoxaban; Venous thromboembolism

Indexed keywords

DALTEPARIN; EDOXABAN; HEMOGLOBIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; BLEEDING; CANCER STAGING; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; EVENT FREE SURVIVAL; HUMAN; METASTASIS; NEOPLASM; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA; VENOUS THROMBOEMBOLISM; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; METHODOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PULMONARY EMBOLISM; RECURRENT DISEASE; SAMPLE SIZE; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADULT; ANTICOAGULANTS; DALTEPARIN; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; NEOPLASMS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; PYRIDINES; RECURRENCE; RESEARCH DESIGN; SAMPLE SIZE; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84983095266     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-06-0452     Document Type: Article

References (29)

1. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122: 1712-1723.
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
3. Lyman GH, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2013; 31: 2189-2204.
4. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
5. Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6): vi85-92.
6. Van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
7. Carrier M, Cameron C, Delluc A, et al. Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Thromb Res 2014; 134: 1214-1219.
8. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
9. Raskob GE, Büller HR, Angchaisuksiri P, et al. Edoxaban for long-term treatment of venous thromboembolism in cancer patients. 55th Ann Meet Am Soc Hematol 2013.
10. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
11. Khorana AA, O’Connell C, Agnelli G, et al. Incidental venous thromboembolism in oncology patients. J Thromb Haemost 2012; 10: 2602-2604.
12. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. J Am Med Assoc 2015; 314: 677-86.
13. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
14. Francis C, Kessler C, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to twelve months. The DALTECAN Study. J Thromb Haemost 2015; Epub ahead of print.
15. Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-589.
16. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
17. Di Nisio M, Lee AYY, Carrier M, et al. Diagnosis and Treatment of Incidental Venous Thromboembolism in Cancer Patients: guidance from the SSC of the ISTH. J Thromb Haemost 2015; Epub ahead of print.
18. O’Connell C, Razavi P, Ghalichi M, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost 2011; 9: 305-311.
19. Van Es N, Bleker SM, Di Nisio M. Cancer-associated unsuspected pulmonary embolism. Thromb Res 2014; 133 (Suppl): S172-178.
20. Kleinjan A, Aggarwal A, Van de Geer A, et al. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 2013; 110: 1-7.
21. Rana P, Levine MN. How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized? J Clin Oncol 2014; 32: 3586-3587.
22. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
23. Salanti G, Higgins JPT, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
24. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
25. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
26. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane database Syst Rev 2014; 7: CD006650.
27. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
28. Büller HR, Prins MH, Lensin AWA, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
29. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.